Cephalon clinical trials

Acquired by Teva Pharmaceutical Industries, Ltd., Oct 14, 2011 · source ↗

The registry lists 81 studies whose lead sponsor is Cephalon. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 23, 2024.

Studies

Recruiting first, then most recently updated. Showing 50 of 81. List all 81 → · All Teva Pharmaceutical Industries, Ltd. studies →

• Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast CancerCompletedNCT00712881Phase 2

  Sponsor listed in the registry: Cephalon, Inc. · First submitted before Cephalon, Inc. became part of Teva Pharmaceutical Industries, Ltd.

• The Nuvigil and Provigil Pregnancy RegistryTerminatedNCT01792583

  Sponsor listed in the registry: Cephalon, Inc. · First submitted after Cephalon, Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety DisorderCompletedNCT00233675Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus ErythematosusTerminatedNCT01240694Phase 3

  Sponsor listed in the registry: Cephalon, Inc. · First submitted before Cephalon, Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)CompletedNCT01135459Phase 2

  Sponsor listed in the registry: Cephalon, Inc. · First submitted before Cephalon, Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain InjuryTerminatedNCT00893789Phase 3

  Sponsor listed in the registry: Cephalon, Inc. · First submitted before Cephalon, Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain InjuryTerminatedNCT00983437Phase 3

  Sponsor listed in the registry: Cephalon, Inc. · First submitted before Cephalon, Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderTerminatedNCT01121536Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other AgentsTerminatedNCT00825227Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)CompletedNCT00079482Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk HerniationCompletedNCT01240876Phase 1/2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderCompletedNCT01305408Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderCompletedNCT01072929Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderCompletedNCT01072630Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent TherapyTerminatedNCT01023880Phase 1/2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential ThrombocytosisCompletedNCT00586651Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell LymphomaCompletedNCT00891839Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal WomenTerminatedNCT01159873Phase 1

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)TerminatedNCT00293111Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.CompletedNCT00214994Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHDCompletedNCT00228540Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00107848Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety DisorderCompletedNCT00236067Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's LymphomaCompletedNCT00069758Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to RituximabCompletedNCT00139841Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)CompletedNCT00236041Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00076349Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough PainCompletedNCT00214955Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough PainCompletedNCT00214942Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety DisorderCompletedNCT00236015Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00107809Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Treatment of Breakthrough Pain in Opioid Tolerant Cancer PatientsCompletedNCT00105287Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil TreatmentCompletedNCT00343811Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough PainCompletedNCT00236093Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety DisorderCompletedNCT00236054Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough PainCompletedNCT00228605Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic PainCompletedNCT00343733Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)CompletedNCT01073163Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGILCompletedNCT00236080Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep DisorderCompletedNCT00078312Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00228566Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)CompletedNCT00078325Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and DepressionCompletedNCT00518986Phase 4

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory PerformanceCompletedNCT00711516Phase 4

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderCompletedNCT00481195Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive DeficitsCompletedNCT00487942Phase 2

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSDCompletedNCT00080288Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive SleepinessCompletedNCT00228553Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag DisorderCompletedNCT00758498Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.

• Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With NarcolepsyCompletedNCT00078377Phase 3

  Sponsor listed in the registry: Cephalon · First submitted before Cephalon became part of Teva Pharmaceutical Industries, Ltd.